Vonafexor (EYP001) in NASH


NASH (Non-Alcoholic SteatoHepatitis) is the most common liver disorder in Western countries and results in liver fat accumulation leading to inflammation and hepatocyte injury. It is estimated that more than 4% of the population has an advanced NASH. Its main consequences are similar to the ones of chronic hepatitis B which are liver fibrosis, cirrhosis and hepato-cellular carcinoma. Currently no treatment exists for this disease which represents an increasing challenge worldwide.

Vonafexor (EYP001) which is an orally bioavailable synthetic non-steroidal, non-bile acid FXR agonist small molecule is also developed in NASH. Most Key Opinion Leaders agree that FXR agonists could become the backbone of any future NASH therapies. It has demonstrated its efficacy in a Stelic mouse model (STAM(TM)) with significant positive impact on most of the NASH key parameters (Fibrosis, Steatosis, Inflammation, Ballooning, triglycerides and NAS). It differentiates from other FXR agonists with a unique chemistry and PK PD profile to possibly provide best-in-class therapeutic index.

Vonafexor (EYP001), is currently evaluated in a phase IIa clinical trial, in patients with advanced NASH, i.e. a fibrosis stage F2 or F3. After the interim safety analysis showing good tolerance, the independent DSMC suggested to pursue the trial to completion as planned.

Key Opinion Leaders

Part under construction